Search research articles
Contact Us
Filters
Showing results (221-230 of 225) with videos related to
Page
of 23
Sort By:
You have reached the last page of results.
This site can display upto 225 results.
Clinical and Translational Radiation Oncology
|
January 24, 2023
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer
Nikhil Yegya-Raman, Timothy P Kegelman, Sang Ho Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alex Watts, et al.
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Cancer Research
|
December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
Arijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
The Lancet. Oncology
|
October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Page
of 23
Search research articles
Search
Showing results (221-230 of 225) with videos related to
Sort By:
Page
of 23
You have reached the last page of results.
This site can display upto 225 results.
Clinical and Translational Radiation Oncology
|
January 24, 2023
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer
Nikhil Yegya-Raman, Timothy P Kegelman, Sang Ho Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alex Watts, et al.
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Cancer Research
|
December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
Arijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
The Lancet. Oncology
|
October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Page
of 23